Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in ...
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 ...
The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed ...
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma. Etentamig, a BCMA/CD3 bispecific antibody, ...
TriNav Advance is the fourth FDA-cleared PEDD device in TriSalus’s portfolio, joining the TriNav Infusion System and TriNav ...
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small ...
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE. In an ...
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 ...
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full ...
This episode makes the case for moving HER2-targeted therapy into the first-line setting. The panel describes how a frontline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results